FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfilePYC Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PYC.AX
PYC Therapeutics Limited Stock AnalysisComprehensive stock analysis for PYC Therapeutics Limited (PYC.AX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisPYC.AX
PYC.AX
PYC Therapeutics Limited
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
PYC.AX
  1. Home
  2. Stocks
  3. PYC Therapeutics Limited

PYC Therapeutics Limited

🇦🇺PYC.AX•ASX

PYC Therapeutics Limited

🇦🇺PYC.AX•ASX

Your view on PYC.AX

Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About PYC Therapeutics Limited

Industry
Biotechnology
Sector
Healthcare
CEO
Rohan Hockings
Headquarters
Harry Perkins Institute of Medical Research, Nedlands, WA, AU
Industry
Biotechnology
Sector
Healthcare
CEO
Rohan Hockings
Headquarters
Harry Perkins Institute of Medical Research, Nedlands, WA, AU
Description

PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials.

PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019.

PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for PYC Therapeutics Limited. Starting points for PYC Therapeutics Limited: EPS -AUD 0.04, beta 1.04 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for PYC Therapeutics Limited. PYC Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for PYC Therapeutics Limited. Trailing twelve-month EPS for PYC Therapeutics Limited stands at -AUD 0.04. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for PYC Therapeutics Limited. PYC Therapeutics Limited has reported as a listed company since 2024. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold PYC.AX12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PALIPalisade Bio, Inc.HealthcareNASDAQ$150.6M
PANCPanacos Pharmaceuticals, Inc.HealthcareOTC$5,367
PAR.AXParadigm Biopharmaceuticals LimitedHealthcareASX—
PARDPoniard Pharmaceuticals, Inc.HealthcareOTC$150
PASGPassage Bio, Inc.HealthcareNASDAQ$12.6M
PBIGFParadigm Biopharmaceuticals LimitedHealthcareOTC$87.9M
PBLAPanbela Therapeutics, Inc.HealthcareOTC$53,889
PBLSParabilis Medicines, Inc.HealthcareNASDAQ$3.3B
PBMPsyence Biomedical Ltd.HealthcareNASDAQ$56,486
PBMWWPsyence Biomedical Ltd. WarrantHealthcareNASDAQ$973
PBYIPuma Biotechnology, Inc.HealthcareNASDAQ$364.5M
PCSAProcessa Pharmaceuticals, Inc.HealthcareNASDAQ$4.4M
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for PYC Therapeutics Limited. Coverage tracks PYC Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of PYC Therapeutics Limited.

PYC.AX AnalysisFair
Past
3
Growth
1
Health
5
Profit
1
Value
1